Vasostatin

Vasostatin-1 produces vasodilation by interfering with intracellular Ca2+ handling in vascular smooth muscle. It reduces the Ca2+ sensitivity of contractile proteins without altering bulk Ca2+ levels, effectively reducing the contractile response at any given Ca2+ concentration. Vasostatin also inhibits endothelin-1-induced vasoconstriction specifically in coronary arterial smooth muscle, making it a selective counterbalance to ET-1 in the coronary circulation. NO-independent vasodilation through cAMP elevation has also been described.

In isolated heart preparations, vasostatin-1 reduces cardiac contractility (negative inotropy) and heart rate (negative chronotropy). These effects are concentration-dependent and distinct from the mechanisms of catestatin (which works via adrenergic pathways). Vasostatin's cardiac effects involve L-type Ca2+ channel modulation and possible reduction in SR Ca2+ loading. The net effect is reduction in cardiac work, potentially beneficial in states of cardiac overload.

In ischemia-reperfusion models, vasostatin-1 pretreatment reduces infarct size and preserves cardiac function via PI3K/Akt-dependent mechanisms and mitochondrial protection. On mast cells, vasostatin inhibits exocytosis of histamine and other inflammatory mediators via cAMP elevation. It also suppresses ConA-stimulated T-cell proliferation, suggesting immunosuppressive properties consistent with the broader autonomic-immune connection embodied in CgA-derived peptides.

Vasostatin-1 selectively dilates coronary arteries in ex vivo preparations with greater potency in human coronary vessels than peripheral arteries. This cardiac selectivity distinguishes it from adrenomedullin and cgrp/" class="wiki-internal-link">CGRP, which dilate both coronary and peripheral vessels. The mechanism involves selective inhibition of ET-1 signaling in coronary tissue. These findings suggest potential utility in coronary vasospasm or Prinzmetal angina, though no clinical studies exist.

Vasostatin-1 at 1-10 nM reduces infarct size by 25-40% in rat and mouse ischemia-reperfusion models when given as pretreatment. The window of protection extends to treatment at the time of reperfusion, suggesting therapeutic potential for acute MI. Mechanisms include PI3K/Akt activation, MPTP inhibition, and reduced oxidative stress. These results parallel catestatin's cardioprotective data, suggesting CgA-derived peptides share a conserved cardioprotective function.

Plasma CgA levels are elevated in heart failure, hypertension, and following myocardial infarction. CgA-derived fragment levels (including vasostatin) correlate with cardiac disease severity and independently predict mortality. Whether elevated CgA fragments represent compensatory cardioprotective responses or markers of sympathoadrenal activation causing harm is debated. CgA measurement is used clinically for neuroendocrine tumor diagnosis where it is highly elevated.